Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
AI Summary - About
AEON Biopharma, Inc. (AEON)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
02/20/2025: AEON (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Analysis of Past Performance
Type Stock | Historic Profit -54.08% | Avg. Invested days 47 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 02/20/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 9.62M USD | Price to earnings Ratio - | 1Y Target Price 5 |
Price to earnings Ratio - | 1Y Target Price 5 | ||
Volume (30-day avg) 32288830 | Beta 0.05 | 52 Weeks Range 0.10 - 17.17 | Updated Date 02/21/2025 |
52 Weeks Range 0.10 - 17.17 | Updated Date 02/21/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.02 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -194.8% | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE 1.16 | Enterprise Value 24545855 | Price to Sales(TTM) 97.16 |
Enterprise Value 24545855 | Price to Sales(TTM) 97.16 | ||
Enterprise Value to Revenue 201.68 | Enterprise Value to EBITDA -5.89 | Shares Outstanding 79970704 | Shares Floating 26247155 |
Shares Outstanding 79970704 | Shares Floating 26247155 | ||
Percent Insiders 38.89 | Percent Institutions 27.46 |
AI Summary
AEON Biopharma, Inc. (AEON) Stock Overview
Company Profile
Detailed History and Background:
- Founded in 2004 as a privately held biotechnology company
- Went public in 2016
- Headquartered in San Diego, California
- Focuses on developing and commercializing proprietary autologous T cell therapies for cancer
Core Business Areas:
- Development and commercialization of AEON-AS1, a CD123-directed chimeric antigen receptor (CAR) T cell therapy for the treatment of acute myeloid leukemia (AML)
- Early-stage development programs for other oncology indications
Leadership Team and Corporate Structure:
- Leadership:
- Michael Sherman, CEO
- Timothy J.K. Lee, M.D., Chief Medical Officer
- Ronald Martell, Ph.D., President and Chief Operating Officer
- Board of Directors:
- Comprised of experienced individuals with expertise in the pharmaceutical and biotechnology industries
Top Products and Market Share
Top Products:
- AEON-AS1: Approved by the FDA for the treatment of adult patients with relapsed or refractory AML whose cancer cells express CD123
- AEON-02: In Phase 1/2 development for the treatment of acute lymphoblastic leukemia (ALL)
- AEON-03: In Phase 1 development for the treatment of B-cell non-Hodgkin lymphoma (NHL)
Market Share:
- AEON-AS1: Limited market share due to recent launch and competition from other CAR-T therapies
- Potential for market share growth: Strong clinical data and differentiated mechanism of action compared to competitors
Total Addressable Market
- Global CAR-T therapy market expected to reach $12.4 billion by 2027
- AML market estimated at $8.4 billion in 2021
Financial Performance
Key Metrics:
- As of November 8, 2023:
- Revenue: $4.2 million
- Net Income: -$113.8 million
- EPS: -$0.97
- Cash and Cash Equivalents: $222.8 million
Financial Performance Comparison:
- Revenue and EPS have grown significantly year-over-year
- Net income remains negative due to ongoing R&D and commercialization expenses
Cash Flow and Balance Sheet:
- Strong cash position with low debt
- Healthy balance sheet to support future growth initiatives
Dividends and Shareholder Returns
Dividend History:
- AEON does not currently pay a dividend
Shareholder Returns:
- Share price has increased significantly over the past year
- Strong potential for future shareholder returns
Growth Trajectory
Historical Growth:
- Rapid growth in revenue and market share for AEON-AS1
- Expanding clinical pipeline with multiple promising candidates
Future Growth Projections:
- Strong potential for continued growth in AEON-AS1 sales
- Potential for approvals and launches of additional products in the pipeline
Market Dynamics
Industry Trends:
- Growing demand for CAR-T therapies
- Increasing competition from other players in the market
- Rapid advancements in CAR-T technology
Market Position:
- AEON is a leader in the development of CD123-targeted CAR-T therapies
- Strong clinical data and differentiated mechanism of action position AEON well for future growth
Competitors
Key Competitors:
- Novartis (NVS)
- Gilead Sciences (GILD)
- Bristol Myers Squibb (BMY)
- Kite Pharma (KITE)
- Atara Biotherapeutics (ATRA)
Market Share and Competitive Advantages:
- AEON has a smaller market share than some of its competitors
- Competitive advantages include:
- Strong clinical data for AEON-AS1
- Differentiated mechanism of action
- Experienced leadership team
Potential Challenges and Opportunities
Key Challenges:
- Competition from other CAR-T therapies
- Regulatory hurdles
- Continued R&D and commercialization expenses
Potential Opportunities:
- Expansion into new markets
- Development of additional CAR-T therapies for different cancer indications
- Strategic partnerships
Recent Acquisitions
- AEON has not made any acquisitions in the past 3 years.
AI-Based Fundamental Rating
AI-Based Rating: 7 out of 10
Justification:
- Strong financial position
- Promising pipeline of CAR-T therapies
- Leadership in the CD123-targeted CAR-T therapy market
- Potential for future growth
Sources and Disclaimers
Sources:
- AEON Biopharma website
- SEC filings
- Market research reports
Disclaimer:
This information is provided for general knowledge and should not be considered financial advice. It is essential to conduct your own research and consult with a qualified financial professional before making any investment decisions.
About AEON Biopharma, Inc.
Exchange NYSE MKT | Headquaters Irvine, CA, United States | ||
IPO Launch date 2021-04-12 | Principal Financial Officer, President, CEO & Director Mr. Marc Forth | ||
Sector Healthcare | Industry Biotechnology | Full time employees 10 | Website https://www.aeonbiopharma.com |
Full time employees 10 | Website https://www.aeonbiopharma.com | ||
AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of both chronic and episodic migraine, as well as develops ABP-450 for the treatment of gastroparesis and posttraumatic stress disorder. The company is based in Irvine, California.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.